# ACROBiosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acrobiosystems

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.acrobiosystems.cn
- Latest round: Series B (Apr 20, 2017)
- Investors on record: 6

## About

Established in 2010 and based in Beijing, China, ACROBiosystems is a biotech company that provides target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.  In 2021, the company was listed on the Shenzhen Stock Exchange.

The company engages in the research and development of recombinant proteins. Its main products include ADC target protein, immune checkpoint protein and multiple transmembrane target protein, etc. Its main products include ADC target protein, immune checkpoint protein and multiple transmembrane target protein, etc.

## Funding rounds

- Series B, Apr 20, 2017 — Cowin Capital, Share Capital, Neovision Capital, Nanjing Gaoke
- Series A, Aug 24, 2015 — Puhua Capital, Lanting Capital

## Investors

- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- Lanting Capital (https://capitalatlas.ai/funds/lanting-capital) — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series B
- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series B
- Nanjing Gaoke — Series B